Synthekine
1505 O'Brien Drive
Menlo Park
CA
94025
United States
Tel: 1 (650) 271-9888
Website: http://www.synthekine.com/
14 articles with Synthekine
-
Money on the Move: June 9-15
6/16/2021
Each week more money pours into the biopharma world. Here's a peek at who's getting a taste of fresh funds this week. -
Synthekine Announces $107.5 Million Oversubscribed Series B Financing to Support Lead Programs to Clinical Proof of Concept, Advance Preclinical Programs and Platform
6/10/2021
Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has closed an oversubscribed $107.5 million Series B financing.
-
Synthekine and Bright Peak made announcements on their Series B rounds, while Hawthorne Effect and Owl Peak Labs also secured their funding. Let us take a look.
-
BioSpace Movers & Shakers, June 4
6/4/2021
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers. -
Synthekine Expands Board of Directors, Management Team and Scientific Advisory Board with New Key Appointments
6/3/2021
Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has appointed Mardi Dier to its board of directors, Robin Knifsend as senior vice president of finance and operations and Antoni Ribas, M.D., Ph.D., to its scientific advisory board.
-
BioSpace Movers & Shakers, May 7
5/7/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Synthekine Licenses Additional Cytokine Programs
4/22/2021
Synthekine Inc., an engineered cytokine therapeutics company, today announced a new agreement with Stanford University to license cytokine partial agonist programs for IL-10, IL-12 and IL-22. These programs augment a growing pipeline of selective cytokine partial agonists at Synthekine that is maturing toward clinical development.
-
Synthekine Presents Data at AACR Annual Meeting 2021 Demonstrating Selective IL-2 Partial Agonist, STK-012, Promotes Anti-Tumor Response without Related Toxicities
4/10/2021
Synthekine Inc., an engineered cytokine therapeutics company, announced preclinical data presented at the American Association of Cancer Research Annual Meeting 2021 demonstrating its alpha/beta selective IL-2 partial agonist, STK-012, induced potent anti-tumor activity while avoiding the toxicities that have hindered the development of IL-2 therapeutics, including vascular leak syndrome.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Synthekine Strengthens Leadership with Board of Directors Expansion and Scientific Advisory Board Formation
2/4/2021
Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has appointed Pablo Cagnoni, M.D., to its board of directors. Dr. Cagnoni brings to Synthekine extensive leadership experience in the biotech industry and a successful track record of oncology drug development.
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Synthekine Presents Data at American Society of Hematology Annual Meeting Showing Orthogonal IL-2 Ligand Drives Deeper and More Durable Response of CD-19 CAR-T
12/7/2020
Synthekine Inc., an engineered cytokine therapeutics company, today announced in vivo data presented at the American Society of Hematology Annual Meeting showing STK-009, its orthogonal IL-2 ligand, improved the efficacy and durability of SYNCAR-001, its CD-19 targeted CAR-T cell therapy modified with an orthogonal IL-2 receptor
-
Engineered cytokine therapeutics company Synthekine announced on Thursday that it has concluded an $82 million Series A funding round.
-
Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune Diseases
9/17/2020
Series A led by Canaan Partners, Samsara BioCapital and The Column Group Foundational research into cytokine structural biology and immune function licensed from Stanford University Nils Lonberg joins founding investors on board of directors